LONDON and NEW YORK , Feb. 27, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has agreed to sell approximately 5.8 million ordinary shares at a price of $13.80 per share.

LONDON and NEW YORK, Feb. 21, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of Dr. Martin Indyk to its Board of Directors. Martin Indyk is an American diplomat who has served in senior

LONDON and NEW YORK, Feb. 05, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes , Ph.D., president and chief executive officer of MeiraGTx , will present at the BIO CEO & Investor

-- Conference call and webcast today, January 31, 2019 at 8:30 a.m. EST -- MeiraGTx to receive $100 million cash upfront payment upon closing -- MeiraGTx to receive 20% net sales royalties and additional potential future milestone payments -- Janssen Pharmaceuticals, Inc.

LONDON and NEW YORK, Jan. 02, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes , Ph.D., president and chief executive officer of MeiraGTx , will present at the J.P.